Global MDMA-assisted Therapy Market Overview:
PTSD is a common and debilitating condition with enormous social and economic costs that affects hundreds of millions of people each year. PTSD develops after a traumatic event such as a serious accident, injuries, or war. Memories can manifest as flashbacks or nightmares, forcing some people to relive terrifying events. There is no medication that can treat PTSD, but some medications can help with symptoms. This is where MDMA Therapy arises. MDMA is a psychoactive drug that acts as a stimulant and releases chemicals in your brain to give you energy, heighten your senses, and increase emotions such as self-awareness and empathy. MDMA -assisted therapy helps to treat PTSD Patients.
- Growing Demand for Antidepressants
- Increase in Number of Autistic Adults
- High Cost of MDMA Drugs and Therapy
- Rising Investment in Healthcare Sector
- Increasing Government Initiatives for MDMA Therapy Awareness
- Risk of MDMA Overdose
- Lack of Awareness in Emerging Economies
The demand for MDMA-assisted Therapy is increasing. Businesses in this sector face global competition from market leaders who control a large share of the market. Companies are differentiating their products from competition by employing environmentally friendly materials and manufacturing techniques. The Leading Players are engaging in strategic global expansion to maintain their Market Position. Players are expected to focus on the creation of new compounds, which would likely drive the worldwide market forward over the forecast period.
Some of the key players profiled in the report are Numinus Wellness (Canada), ATAI Life Sciences (Germany), Seelos Therapeutics (United States), Awakn Life Sciences (Canada), Field Trip Health (Canada), Cybin (Canada), Novamind (Canada), Mount Sinai Health System (United States), COMPASS Pathways PLC (United Kingdom) and MindMed (United States). Analyst at AMA Research see Canada Players to retain maximum share of Global MDMA-assisted Therapy market by 2026. Considering Market by Therapy, the sub-segment i.e. Cognitive Behavioural Therapy will boost the MDMA-assisted Therapy market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the MDMA-assisted Therapy market. Considering Market by End User, the sub-segment i.e. Hospital will boost the MDMA-assisted Therapy market.
In September 2021 Awakn had announced the acquisition of MDMA Research Rights from Imperial College London. This information will aid Awakn's progress by allowing for a more efficient design and execution of its clinical programme. Awakn will now be able to move its clinical research into a phase IIb randomised controlled trial (RCT) in the United Kingdom. This is part of its strategy to obtain marketing authorization for MDMA to treat AUD in both the United Kingdom and the European Union, which has a population of 400 million people.
What Can be Explored with the MDMA-assisted Therapy Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global MDMA-assisted Therapy Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in MDMA-assisted Therapy
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global MDMA-assisted Therapy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in MDMA-assisted Therapy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture and Capitalist, New entrants/investors, Analysts and Strategic Business Partners, Hospital, Clinics and End-use industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.